Literature DB >> 16837931

A subtype of multiple sclerosis defined by an activated immune defense program.

L G M van Baarsen1, T C T M van der Pouw Kraan, J J Kragt, J M C Baggen, F Rustenburg, T Hooper, J F Meilof, M J Fero, C D Dijkstra, C H Polman, C L Verweij.   

Abstract

Given the heterogeneous nature of multiple sclerosis (MS), we applied DNA microarray technology to determine whether variability is reflected in peripheral blood (PB) cells. In this study, we studied whole-blood gene expression profiles of 29 patients with relapsing-remitting MS (RRMS) and 25 age- and sex-matched healthy controls. We used microarrays with a complexity of 43K cDNAs. The data were analyzed using sophisticated pathway-level analysis in order to provide insight into the deregulated peripheral immune response programs in MS. We found a remarkable elevated expression of a spectrum of genes known to be involved in immune defense in the PB of MS patients compared to healthy individuals. Cluster analysis revealed that the increased expression of these genes was characteristic for approximately half of the patients. In addition, the gene signature in this group of patients was comparable with a virus response program. We conclude that the transcriptional signature of the PB cells reflects the heterogeneity of MS and defines a sub-population of RRMS patients, who exhibit an activated immune defense program that resembles a virus response program, which is supportive for a link between viruses and MS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837931     DOI: 10.1038/sj.gene.6364324

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  30 in total

Review 1.  Interferons in autoimmune and inflammatory diseases: regulation and roles.

Authors:  Divaker Choubey; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

2.  Different strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathway.

Authors:  Spyridon Stavrou; Zongdi Feng; Stanley M Lemon; Raymond P Roos
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future.

Authors:  Philip L De Jager
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

4.  Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

Authors:  T C T M van der Pouw Kraan; C A Wijbrandts; L G M van Baarsen; A E Voskuyl; F Rustenburg; J M Baggen; S M Ibrahim; M Fero; B A C Dijkmans; P P Tak; C L Verweij
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

5.  Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Ingo Kleiter; Jian Song; Dominika Lukas; Maruf Hasan; Bernhard Neumann; Andrew L Croxford; Xiomara Pedré; Nadine Hövelmeyer; Nir Yogev; Alexander Mildner; Marco Prinz; Elena Wiese; Kurt Reifenberg; Stefan Bittner; Heinz Wiendl; Lawrence Steinman; Christoph Becker; Ulrich Bogdahn; Markus F Neurath; Andreas Steinbrecher; Ari Waisman
Journal:  Brain       Date:  2010-03-30       Impact factor: 13.501

Review 6.  Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.

Authors:  Tineke Cantaert; Dominique Baeten; Paul P Tak; Lisa G M van Baarsen
Journal:  Arthritis Res Ther       Date:  2010-10-28       Impact factor: 5.156

Review 7.  Type I interferon in organ-targeted autoimmune and inflammatory diseases.

Authors:  Mary K Crow
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

8.  Extracellular 2'5'-oligoadenylate synthetase 2 mediates T-cell receptor CD3-ζ chain down-regulation via caspase-3 activation in oral cancer.

Authors:  Asif A Dar; Trupti N Pradhan; Dakshayni P Kulkarni; Sagar U Shah; Kanury V Rao; Devendra A Chaukar; Anil K D'Cruz; Shubhada V Chiplunkar
Journal:  Immunology       Date:  2015-12-27       Impact factor: 7.397

9.  Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.

Authors:  Lisa Gm van Baarsen; Carla A Wijbrandts; François Rustenburg; Tineke Cantaert; Tineke Ctm van der Pouw Kraan; Dominique L Baeten; Ben Ac Dijkmans; Paul P Tak; Cornelis L Verweij
Journal:  Arthritis Res Ther       Date:  2010-01-22       Impact factor: 5.156

10.  Constrained mixture estimation for analysis and robust classification of clinical time series.

Authors:  Ivan G Costa; Alexander Schönhuth; Christoph Hafemeister; Alexander Schliep
Journal:  Bioinformatics       Date:  2009-06-15       Impact factor: 6.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.